WO2007044085A3 - Composes heteroaryle et leurs utilisations en tant qu'agents therapeutiques - Google Patents

Composes heteroaryle et leurs utilisations en tant qu'agents therapeutiques Download PDF

Info

Publication number
WO2007044085A3
WO2007044085A3 PCT/US2006/019359 US2006019359W WO2007044085A3 WO 2007044085 A3 WO2007044085 A3 WO 2007044085A3 US 2006019359 W US2006019359 W US 2006019359W WO 2007044085 A3 WO2007044085 A3 WO 2007044085A3
Authority
WO
WIPO (PCT)
Prior art keywords
therapeutic agents
heteroaryl compounds
mammal
formula
disclosed
Prior art date
Application number
PCT/US2006/019359
Other languages
English (en)
Other versions
WO2007044085A2 (fr
Inventor
Sultan Chowdhury
Original Assignee
Xenon Pharmaceuticals Inc
Roth Carol J
Sultan Chowdhury
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xenon Pharmaceuticals Inc, Roth Carol J, Sultan Chowdhury filed Critical Xenon Pharmaceuticals Inc
Publication of WO2007044085A2 publication Critical patent/WO2007044085A2/fr
Publication of WO2007044085A3 publication Critical patent/WO2007044085A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing alicyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne des procédés permettant de traiter une maladie ou une affection médiée par SCD chez un mammifère, de préférence un humain. Les procédés selon l'invention consistent à administrer à un mammifère nécessitant un tel traitement un composé de formule (I), dans laquelle J, K, L, M, W, V, R2 et R3 sont définis. L'invention concerne également des compositions pharmaceutiques comprenant les composés de la formule (I).
PCT/US2006/019359 2005-05-19 2006-05-19 Composes heteroaryle et leurs utilisations en tant qu'agents therapeutiques WO2007044085A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US68256905P 2005-05-19 2005-05-19
US60/682,569 2005-05-19

Publications (2)

Publication Number Publication Date
WO2007044085A2 WO2007044085A2 (fr) 2007-04-19
WO2007044085A3 true WO2007044085A3 (fr) 2007-06-28

Family

ID=37872352

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/019359 WO2007044085A2 (fr) 2005-05-19 2006-05-19 Composes heteroaryle et leurs utilisations en tant qu'agents therapeutiques

Country Status (1)

Country Link
WO (1) WO2007044085A2 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8859575B2 (en) 2013-03-06 2014-10-14 Janssen Pharmaceutica Nv Benzoimidazol-2-yl pyrimidine modulators of the histamine h4 receptor
US9365548B2 (en) 2006-03-31 2016-06-14 Janssen Pharmaceutica Nv Benzoimidazol-2-yl pyrimidines and pyrazines as modulators of the histamine H4 receptor
US9371311B2 (en) 2008-06-30 2016-06-21 Janssen Pharmaceutica Nv Benzoimidazol-2-yl pyrimidine derivatives
US12098146B2 (en) 2020-01-24 2024-09-24 Janssen Pharmaceutica Nv Compounds and uses thereof

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20090047458A (ko) 2006-08-08 2009-05-12 사노피-아벤티스 아릴아미노아릴-알킬-치환된 이미다졸리딘-2,4-디온, 이의 제조방법, 이들 화합물을 포함하는 약제 및 이의 용도
EP2086970B1 (fr) 2006-08-24 2014-02-26 Novartis AG Dérivés de 2-(pyrazin-2-yl)-thiazole et de 2-(1h pyrazol-3-yl)-thiazole et composés similaires en tant qu' inhibiteurs de stearoyl-coa desaturase (scd) pour le traitement de maladies metaboliques, cardiovasculaires et d'autres maladies
WO2008139845A1 (fr) * 2007-04-24 2008-11-20 Daiichi Sankyo Company, Limited Nouveau dérivé amide
US8470841B2 (en) 2008-07-09 2013-06-25 Sanofi Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof
WO2010068601A1 (fr) 2008-12-08 2010-06-17 Sanofi-Aventis Hydrate de fluoroglycoside hétéroaromatique cristallin, ses procédés de fabrication, ses procédés d'utilisation et compositions pharmaceutiques le contenant
CA2750564A1 (fr) 2009-02-17 2010-08-26 Merck Canada Inc. Nouveaux composes spiro utiles comme inhibiteurs de la stearoyl-coenzyme a delta-9 desaturase
WO2011011872A1 (fr) 2009-07-28 2011-02-03 Merck Frosst Canada Ltd. Nouveaux composés spiro utiles en tant qu'inhibiteurs de la stéaroyl-coenzyme a delta-9 désaturase
RU2012111354A (ru) 2009-08-26 2013-10-10 Санофи Новые кристаллические гидраты фторгликозидов, содержащие их фармацевтические препараты и их использование
US20130012709A1 (en) 2009-09-10 2013-01-10 Centre National De La Recherche Scientifique NOVEL INHIBITORS OF STEAROYL-CoA-DESATURASE-1 AND THEIR USES
EP2683699B1 (fr) 2011-03-08 2015-06-24 Sanofi Dérivés oxathiazine di- et tri-substitués, procédé pour leur préparation, utilisation en tant que médicament, agent pharmaceutique contenant ces dérivés et utilisation
WO2012120054A1 (fr) 2011-03-08 2012-09-13 Sanofi Dérivés oxathiazine di- et tri-substitués, procédé pour leur préparation, utilisation en tant que médicament, agent pharmaceutique contenant ces dérivés et utilisation
WO2012120056A1 (fr) 2011-03-08 2012-09-13 Sanofi Dérivés oxathiazine tétra-substitués, procédé pour leur préparation, utilisation en tant que médicament, agent pharmaceutique contenant ces dérivés et utilisation
US8828995B2 (en) 2011-03-08 2014-09-09 Sanofi Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
US8901114B2 (en) 2011-03-08 2014-12-02 Sanofi Oxathiazine derivatives substituted with carbocycles or heterocycles, method for producing same, drugs containing said compounds, and use thereof
RU2014119426A (ru) 2011-10-15 2015-11-20 Дженентек, Инк. Способы применения антагонистов scd1
CA2873817A1 (fr) 2012-05-22 2013-11-28 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Inhibiteurs selectifs de cellules indifferenciees
MY184366A (en) 2014-02-14 2021-04-01 Takeda Pharmaceuticals Co Pyrazines modulators of gpr6
UY36391A (es) 2014-11-05 2016-06-01 Flexus Biosciences Inc Compuestos moduladores de la enzima indolamina 2,3-dioxigenasa (ido1), sus métodos de síntesis y composiciones farmacèuticas que las contienen
JO3637B1 (ar) 2015-04-28 2020-08-27 Janssen Sciences Ireland Uc مركبات بيرازولو- وترايازولو- بيريميدين مضادة للفيروسات rsv
US11970486B2 (en) 2016-10-24 2024-04-30 Janssen Pharmaceutica Nv Compounds and uses thereof
BR112019013954A2 (pt) 2017-01-06 2020-02-11 Yumanity Therapeutics, Inc. Métodos para o tratamento de distúrbios neurológicos
EP3700934A4 (fr) 2017-10-24 2021-10-27 Yumanity Therapeutics, Inc. Composés et utilisations de ces composés
TW201932470A (zh) 2017-11-29 2019-08-16 愛爾蘭商健生科學愛爾蘭無限公司 具有抗ｒｓｖ活性之吡唑并嘧啶
EA202091835A1 (ru) 2018-01-31 2020-10-20 Янссен Сайенсиз Айрлэнд Анлимитед Компани Замещенные циклоалкилом пиразолопиримидины, обладающие активностью против rsv
AU2019260109B2 (en) 2018-04-23 2023-07-13 Janssen Sciences Ireland Unlimited Company Heteroaromatic compounds having activity against RSV
WO2022147246A1 (fr) 2020-12-30 2022-07-07 Tyra Biosciences, Inc. Composés d'indazole utilisés en tant qu'inhibiteurs de kinase

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005011655A2 (fr) * 2003-07-30 2005-02-10 Xenon Pharmaceuticals Inc. Derives de pyridazine et leur utilisation en tant qu'agents therapeutiques
WO2005011656A2 (fr) * 2003-07-30 2005-02-10 Xenon Pharmaceuticals Inc. Derives pyridyle et leur utilisation en tant qu'agents therapeutiques
WO2005011657A2 (fr) * 2003-07-30 2005-02-10 Xenon Pharmaceuticals Inc. Derives de piperazine et utilisation comme agents therapeutiques
WO2005040144A1 (fr) * 2003-10-15 2005-05-06 Glaxo Group Limited Derives de diazepine 1-benzoyle substitues en tant qu'agonistes de recepteur d'histamine selective h3
WO2006014168A1 (fr) * 2004-07-06 2006-02-09 Xenon Pharmaceuticals Inc. Dérivés de nicotinamide et utilisation de ceux-ci comme agents thérapeutiques
WO2006034446A2 (fr) * 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Derives heterocycliques et leur utilisation comme agents therapeutiques
WO2006034441A1 (fr) * 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Derives heterocycliques et leur utilisation en tant qu'inhibiteurs de la stearoyl-coa desaturase

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005011655A2 (fr) * 2003-07-30 2005-02-10 Xenon Pharmaceuticals Inc. Derives de pyridazine et leur utilisation en tant qu'agents therapeutiques
WO2005011656A2 (fr) * 2003-07-30 2005-02-10 Xenon Pharmaceuticals Inc. Derives pyridyle et leur utilisation en tant qu'agents therapeutiques
WO2005011657A2 (fr) * 2003-07-30 2005-02-10 Xenon Pharmaceuticals Inc. Derives de piperazine et utilisation comme agents therapeutiques
WO2005040144A1 (fr) * 2003-10-15 2005-05-06 Glaxo Group Limited Derives de diazepine 1-benzoyle substitues en tant qu'agonistes de recepteur d'histamine selective h3
WO2006014168A1 (fr) * 2004-07-06 2006-02-09 Xenon Pharmaceuticals Inc. Dérivés de nicotinamide et utilisation de ceux-ci comme agents thérapeutiques
WO2006034446A2 (fr) * 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Derives heterocycliques et leur utilisation comme agents therapeutiques
WO2006034441A1 (fr) * 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Derives heterocycliques et leur utilisation en tant qu'inhibiteurs de la stearoyl-coa desaturase

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9365548B2 (en) 2006-03-31 2016-06-14 Janssen Pharmaceutica Nv Benzoimidazol-2-yl pyrimidines and pyrazines as modulators of the histamine H4 receptor
US9371311B2 (en) 2008-06-30 2016-06-21 Janssen Pharmaceutica Nv Benzoimidazol-2-yl pyrimidine derivatives
US8859575B2 (en) 2013-03-06 2014-10-14 Janssen Pharmaceutica Nv Benzoimidazol-2-yl pyrimidine modulators of the histamine h4 receptor
US9278952B2 (en) 2013-03-06 2016-03-08 Janssen Pharmaceutica Nv Benzoimidazol-2-yl pyrimidine modulators of the histamine H4 receptor
US9434715B2 (en) 2013-03-06 2016-09-06 Janssen Pharmaceutica Nv Benzoimidazol-2-yl pyrimidine modulators of the histamine H4 receptor
US12098146B2 (en) 2020-01-24 2024-09-24 Janssen Pharmaceutica Nv Compounds and uses thereof

Also Published As

Publication number Publication date
WO2007044085A2 (fr) 2007-04-19

Similar Documents

Publication Publication Date Title
WO2007044085A3 (fr) Composes heteroaryle et leurs utilisations en tant qu'agents therapeutiques
WO2007046867A3 (fr) Derives de piperidine et leurs utilisations comme agents therapeutiques
WO2007046868A3 (fr) Derives de thiazolidine et leurs utilisations en tant qu’agents therapeutiques
WO2006086447A3 (fr) Derives de pyridazine et leur utilisation en tant qu'agents therapeutiques
WO2007130075A8 (fr) Derives aminothiazole utilises en tant qu'inhibiteurs de la stearoyle-coa desaturase humaine
WO2006125181A3 (fr) Derives piperidiniques: utilisation comme agents therapeutiques
EP2269610A3 (fr) Dérivés hétérocycliques et leur utilisation en tant qu'inhibiteurs de la stearoyl-coa desaturase
WO2007136746A3 (fr) Composés macrocycliques et leurs utilisations en tant qu'agents thérapeutiques
EP2266569A3 (fr) Dérivés hétérocycliques et leur utilisation en tant qu'inhibiteurs de la stearoyl-coa desaturase
WO2005011653A3 (fr) Derives de pyridazine et utilisation de ceux-ci en tant qu'agents therapeutiques
BRPI0418939A (pt) derivados de nicotinamida e sua utilização como agentes terapêuticos
WO2006125178A3 (fr) Composes de pyridazine tricycliques et leurs utilisations comme agents therapeutiques
WO2005011655A3 (fr) Derives de pyridazine et leur utilisation en tant qu'agents therapeutiques
TW200626138A (en) Heterocyclic derivatives and their use as therapeutic agents
WO2005011657A3 (fr) Derives de piperazine et utilisation comme agents therapeutiques
WO2005011654A3 (fr) Derives de pyridyle et utilisation de ceux-ci en tant qu'agents therapeutiques
WO2007138472A3 (fr) Dérivés de la triazolopyridazine
TW200626592A (en) Heterocyclic derivatives and their use as therapeutic agents
WO2006032342A3 (fr) Medicament contenant des composes carbonyles et leur utilisation
WO2007135527A3 (fr) Composés de benzimidazolyle
WO2006034446A3 (fr) Derives heterocycliques et leur utilisation comme agents therapeutiques
GEP20084452B (en) Sulfonamide derivatives for the treatment of diseases
WO2008054454A3 (fr) Dérivés hétérocycliques contenant de l'azote, compositions pharmaceutiques, et leurs procédés d'utilisations en tant qu'agents antiviraux
WO2006044362A3 (fr) Antagonistes du recepteur 1 de n-sulfonylpiperidine cannabinoide
WO2008087367A3 (fr) Derives de (phenylthiazolyl)-phenyl-propan-1-one et de (phenyloxazodyl)-phenyl-propan-1-one substitues, preparations et utilisations

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

NENP Non-entry into the national phase

Ref country code: RU

122 Ep: pct application non-entry in european phase

Ref document number: 06844103

Country of ref document: EP

Kind code of ref document: A2